Showing results (1-10 of 78) with videos related to
Sort By:
Pageof 8
Postgraduate Medicine|February 28, 1998
Corticosteroids in rheumatic disease. Understanding their effects is key to their useR F van VollenhovenClinical and Experimental Rheumatology|November 24, 2004
Switching between biological agentsR F van VollenhovenClinical and Experimental Rheumatology|November 24, 2004
Benefits and risks of biological agents: lymphomasR F van VollenhovenRheumatic Diseases Clinics of North America|April 18, 2000
Dehydroepiandrosterone in systemic lupus erythematosusR F van VollenhovenCurrent Opinion in Rheumatology|January 1, 1995
Adhesion molecules, sex steroids, and the pathogenesis of vasculitis syndromesR F van VollenhovenJournal of Internal Medicine|June 17, 2018
Genotypes, phenotypes and treatment with immunomodulators in the rheumatic diseasesR F van VollenhovenJournal of Internal Medicine|January 26, 2011
When to initiate and discontinue biologic treatments for rheumatoid arthritis?K Chatzidionysiou, R F van VollenhovenScandinavian Journal of Rheumatology|December 20, 2007
Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURER F van Vollenhoven, L KlareskogScandinavian Journal of Rheumatology|January 5, 2013
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohortK Chatzidionysiou, R F van VollenhovenPageof 8